Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and…
Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level three (300×106 cells per infusion) with no…